NeuroPace (NASDAQ:NPCE) Research Coverage Started at UBS Group

UBS Group started coverage on shares of NeuroPace (NASDAQ:NPCE) in a research report report published on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a $17.00 price objective on the stock.

A number of other equities research analysts also recently weighed in on NPCE. JPMorgan Chase & Co. boosted their price target on shares of NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. Wells Fargo & Company cut their price target on NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 13th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $15.33.

NeuroPace Stock Performance

NASDAQ NPCE opened at $14.02 on Tuesday. NeuroPace has a 1-year low of $5.45 and a 1-year high of $18.15. The company has a 50 day moving average of $11.22 and a 200-day moving average of $8.56. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. The firm has a market cap of $418.47 million, a price-to-earnings ratio of -14.02 and a beta of 2.02.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.07. The business had revenue of $21.06 million for the quarter, compared to analysts’ expectations of $19.33 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. During the same period in the prior year, the firm earned ($0.28) earnings per share. On average, equities analysts forecast that NeuroPace will post -1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NeuroPace

Several institutional investors have recently added to or reduced their stakes in NPCE. JPMorgan Chase & Co. boosted its position in shares of NeuroPace by 106.3% during the third quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock worth $84,000 after buying an additional 6,181 shares during the period. Rhumbline Advisers bought a new position in shares of NeuroPace during the 2nd quarter worth approximately $111,000. Financial Advocates Investment Management raised its holdings in shares of NeuroPace by 20.0% in the third quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock valued at $125,000 after purchasing an additional 3,000 shares during the last quarter. Barclays PLC raised its holdings in shares of NeuroPace by 346.0% in the third quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after purchasing an additional 16,007 shares during the last quarter. Finally, XTX Topco Ltd lifted its position in shares of NeuroPace by 56.1% in the second quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock worth $182,000 after purchasing an additional 8,643 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.